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Background: Prior retrospective studies of patients with ischemic left ventricular (LV) dysfunction suggest that severity of LV remodeling affects 
the relation between myocardial viability and survival with surgical (CABG) or medical (MED) therapy, such that patients who benefit from CABG are 
those with viable myocardium and lower end systolic volume (ESVI). However, this has not been tested prospectively.
methods: We assessed the interaction of ESVI, myocardial viability and survival in patients in the prospective STICH Trial viability substudy (n=601, 
age 61±9 yrs, ejection fraction ≤35%), who were randomized to CABG or MED with median follow-up 5.1 yrs. Median ESVI was 84 ml/m2. Myocardial 
viability was assessed by SPECT or dobutamine echo using prespecified criteria.
results: Mortality rates were highest among patients with larger ESVI and no viability compared to other subgroups (p=0.001). However, no 
interaction was observed between ESVI, viability status, and treatment assignment to CABG (Table). Specifically, lower ESVI and viable myocardium 
were not associated with a greater reduction in mortality with CABG compared to MED. When ESVI and viability were assessed as continuous rather 
than dichotomous variables, the results were similar.
conclusion: Among patients with ischemic cardiomyopathy, those with greater LVESVI and no substantial viability have worse prognosis. However, 
the effect of CABG relative to MED is not differentially influenced by the combination of these two factors.
 
